NCT00768079View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 2, 2009

Primary Completion Date

December 17, 2010

Study Completion Date

March 10, 2011

Conditions
Asthma
Interventions
OTHER

Placebo

A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.

BIOLOGICAL

Benralizumab

A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.

Trial Locations (11)

2903

Research Site, Providence

11040

Research Site, New Hyde Park

11554

Research Site, East Meadow

27834

Research Site, Greenville

33613

Research Site, Tampa

44109

Research Site, Cleveland

48202

Research Site, Detroit

01199

Research Site, Springfield

11794-8350

Research Site, Stony Brook

T6G 2R3

Research Site, Edmonton

B3H 3A7

Research Site, Halifax

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY